1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

25 Mar 2020
Admin
News Article

Design Therapeutics Launches With $45 Million To Develop A New Class Of Disease-Modifying Therapies For Serious Degenerative Disorders

Design Therapeutics Announced Today That It Is Launching To Create And Develop A New Class Of Therapies For Patients With Serious Degenerative Disorders Caused By Nucleotide Repeat Expansions. The Company Has Closed A $45 Million Series A Financing Led By Sr One, With Participation From Cormorant Asset Management, Quan Capital And Westriver Group, To Advance Its Lead Therapeutic Candidate Into Clinical Development For The Treatment Of Friedreich&Rsquo;S Ataxia, And Support Advancement Of Its Discovery Programs For Multiple Other Degenerative Diseases, Including Fragile X Syndrome And Myotonic Dystrophy.Nucleotide Repeat Disorders Are A Set Of Genetic Disorders Caused By Repeat Expansion In Certain Genes. Depending On Where It Is Located, The Repeat May Cause A Change In The Regulation Of Gene Expression Or Produce A Toxic Gene Product, All Of Which Are Recognized As Significant Contributors To Degenerative Diseases. Design Therapeutics In-Licensed Its Technology From The Wisconsin Alumni Research Foundation (Warf), And Aims To Take A Unique Approach To Treatment And Provide Hope For Patients With Degenerative Disorders.Design Therapeutics Was Co-Founded By Pratik Shah, Ph.D., And Aseem Ansari, Ph.D. Dr. Shah Serves As Chairman Of The Board At Ars Pharmaceuticals, And Prior To That, Until Its Acquisition By Sanofi, Was Chairman Of Synthorx. Earlier, Dr. Shah Was President And Chief Executive Officer Of Auspex Pharmaceuticals Until Its Acquisition By Teva In 2015. Dr. Ansari Currently Serves As Chair Of The Department Of Chemical Biology And Therapeutics At St. Jude Children&Rsquo;S Research Hospital. Previously, Dr. Ansari Was A Faculty Member At The University Of Wisconsin, Where During His Tenure, He Helped Execute The License Agreement With Warf. Design Therapeutics&Rsquo; Leadership Team Also Includes Sean Jeffries, Ph.D., Chief Business Officer, Formerly With The Boston Consulting Group.&Ldquo;Significant Industry Advancements Have Led To The Understanding Of Root Causes Of Multiple Nucleotide Repeat Disorders, However, There Remain Few To No Therapeutic Options That Slow The Progression Or Reverse The Course Of Disease,&Rdquo; Said Dr. Shah. &Ldquo;Our Company Was Founded With A Goal Of Designing A New Class Of Small Molecule Therapies That Address The Core Etiology Of Diseases To Deliver A Biological Effect Typically Only Seen With Complex Molecules. The Collective Insights Of Our Team, Along With Our Financial Strength, Position Us To Transition Into A Clinical-Stage Company To Explore The Corrective Benefit Of Our Programs

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!